Sign Up to like & get
recommendations!
0
Published in 2020 at "Hematology/oncology and stem cell therapy"
DOI: 10.1016/j.hemonc.2020.07.001
Abstract: Carfilzomib is an irreversible proteasome inhibitor currently approved for the treatment of relapsed multiple myeloma. It has been implicated as a cause of thrombotic microangiopathy (TMA) in several case reports. The incidence, risk factors, and…
read more here.
Keywords:
treatment;
case;
carfilzomib induced;
carfilzomib ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "International Immunopharmacology"
DOI: 10.1016/j.intimp.2018.11.023
Abstract: &NA; Acute lung injury (ALI) due to chemotherapy occurs frequently. It presents a challenge for clinicians managing therapies for different types of cancers. Carfilzomib (Kyprolis™) is a new proteasome inhibitor that shows promise for the…
read more here.
Keywords:
carfilzomib induced;
induced lung;
lung injury;
inflammation ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Blood advances"
DOI: 10.1182/bloodadvances.2018027532
Abstract: Rapid initiation of eculizumab mitigates progression of carfilzomib-induced aHUS. Development of carfilzomib-induced aHUS may be associated with heterozygous CFHR3-CFHR1 deletion.
read more here.
Keywords:
cfhr3 cfhr1;
induced ahus;
may associated;
heterozygous cfhr3 ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms222010956
Abstract: Background: Carfilzomib is a first-line proteasome inhibitor indicated for relapsed/refractory multiple myeloma (MM), with its clinical use being hampered by cardiotoxic phenomena. We have previously established a translational model of carfilzomib cardiotoxicity in young adult…
read more here.
Keywords:
metformin;
carfilzomib induced;
model;
cardiotoxicity ... See more keywords